Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 3Lymphoid 3Other hematologic neoplasm 2Genitourinary 2Gastrointestinal 2Breast 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Spinal Cord Neoplasms 1Optic Nerve Glioma 1Medulloblastoma 1Familial ependymoma 1Dendritic Cell Sarcoma, Interdigitating 1Choroid Plexus Neoplasms 1Burkitt Lymphoma 1Astrocytoma 1

Interventions

Radiotherapy 220Doxorubicin 210Cyclophosphamide 210Temozolomide 182Ifosfamide 121Filgrastim 111Imatinib Mesylate 104Etoposide 101Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 80Irinotecan 79pembrolizumab 75Radiation 69Carboplatin 65Methotrexate 62pazopanib 61Nivolumab 58Cisplatin 58fludarabine phosphate 57Peripheral Blood Stem Cell Transplantation 57Surgical Procedures, Operative 56Specimen Handling 56Trabectedin 52Docetaxel 50Biopsy 50Busulfan 49Melphalan 46Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ispinesib × Sarcoma × Clear all
NCT00363272 2013-01-16

Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
CNSLymphoidSarcoma

Familial ependymoma, Astrocytoma, Burkitt Lymphoma, Medulloblastoma, Spinal Cord Neoplasms, Choroid Plexus Neoplasms, Optic Nerve Glioma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡